Business Description
XBiotech Inc
NAICS : 325410
SIC : 3741
ISIN : CA98400H1029
Total Employee Number:
87Description
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -10.9 | |||||
3-Year EPS without NRI Growth Rate | -16.8 | |||||
3-Year FCF Growth Rate | -37.6 | |||||
3-Year Book Growth Rate | -16.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.18 | |||||
9-Day RSI | 43.32 | |||||
14-Day RSI | 46.26 | |||||
3-1 Month Momentum % | 1.23 | |||||
6-1 Month Momentum % | -7.66 | |||||
12-1 Month Momentum % | -22.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 39.03 | |||||
Quick Ratio | 39.03 | |||||
Cash Ratio | 38.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -25.41 | |||||
ROA % | -24.4 | |||||
ROIC % | -197.53 | |||||
3-Year ROIIC % | -1403.08 | |||||
ROC (Joel Greenblatt) % | -170.01 | |||||
ROCE % | -24.97 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 2.15 | |||||
PB Ratio | 0.52 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | 2.31 | |||||
EV-to-EBITDA | 2.41 | |||||
EV-to-FCF | 2.18 | |||||
Price-to-GF-Value | 13.33 | |||||
| Price-to-Net-Current-Asset-Value | 0.63 | |||||
| Price-to-Net-Cash | 0.63 | |||||
Earnings Yield (Greenblatt) % | 43.29 | |||||
FCF Yield % | -60.41 |
XBiotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XBiotech Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 31 days | ||
| General meeting for 2026 | 2026-07-24 | In 11 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 2.08 (-0.95%) | ||
| Annual report for 2025 | 2026-03-13 | 2.00 (+0.50%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 2.24 (+6.67%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 2.52 (+0.00%) | ||
| General meeting for 2025 | 2025-06-20 10:00 | 2.22 (-0.89%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 2.58 (+0.00%) | ||
| Annual report for 2024 | 2025-03-18 | 2.94 (+0.00%) |
Show
Entries
Press Release
Articles on XBiotech Inc
No articles.